JGJun Gu

Jun Gu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jun Gu has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Jianhua Lu

    Department of General Surgery and Laboratory of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, People’s Republic of China

    3 shared publications
  • Xiaoling Song

    Department of General Surgery and Laboratory of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, People’s Republic of China

    3 shared publications
  • Xuefeng Wang

    Department of General Surgery and Laboratory of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, People’s Republic of China

    3 shared publications
  • Zheng Wang

    Department of General Surgery and Laboratory of General Surgery, Xinhua Hospital Affiliated to Shanghai Jiao Tong University, School of Medicine, Shanghai, People’s Republic of China

    3 shared publications
  • Bin Ye

    Department of Gastroenterology, Lishui City Central Hospital and the Fifth Affiliated Hospital of Wenzhou Medical University, Lishui, People’s Republic of China

    2 shared publications
  • Bingtai Zhang

    Department of General Surgery, Shanxi Medical University Second Hospital, Taiyuan, People’s Republic of China

    2 shared publications

Latest Publications

  • Open Access

    Machine Learning–Driven Prognostic Model Integrating Lymphocyte‐to‐C‐Reactive Protein Ratio and TNM Staging in Gallbladder Cancer

    by Mingyang Wang, Zhengyu Chen, Fusheng E, Jun Gu, Runfa Bao

    Background: A comprehensive preoperative assessment of the patient's physical condition is crucial for predicting the prognosis of patients undergoing radical cholecystectomy for gallbladder cancer (GBC). This study aimed to develop a prognostic model integrating preoperative hematological parameters and clinical information to predict postoperative survival in patients with GBC. Methods: Patients who underwent radical cholecystectomy for GBC between 2000 and 2024 at Xinhua Hospital, affiliated with Shanghai Jiao Tong University School of Medicine, and Shigatse People's Hospital were included in this study. Data on demographic features, clinical parameters, laboratory results, and clinical outcomes were collected. Univariate and multivariate Cox regression analyses, time‐dependent ROC curve analysis, and the least absolute shrinkage and selection operator (LASSO) regression were used to identify the key factors for model development. Various machine learning models were constructed based on these findings. Internal validation assessed model stability, while clinical decision analysis evaluated its practical utility. Results: A total of 184 patients were included, with a mean age of 67 years. Key predictors identified through univariate and multivariate Cox regression, time‐dependent ROC, and LASSO analyses were the lymphocyte‐to‐C‐reactive protein ratio (LCR) and tumor‐node‐metastasis (TNM) staging. The best‐performing model was logistic regression, with the following area under the curve (AUC) values: for the training set, 0.785 at 1 year, 0.853 at 2 years, and 0.873 at 3 years; and for the test set, 0.800 at 1 year, 0.870 at 2 years, and 0.872 at 3 years. Clinical decision analysis confirmed the model's clinical applicability. Conclusion: The machine learning model incorporating LCR and TNM staging is a robust tool for predicting postoperative survival following radical resection for GBC.


  • Retraction

    Retraction Note: Chloride intracellular channel 1 (CLIC1) is activated and functions as an oncogene in pancreatic cancer

    by Jianhua Lu, Qian Dong, Bingtai Zhang, Xuefeng Wang, Bin Ye, Fei Zhang, Xiaoling Song, Guofeng Gao, Jiasheng Mu, Zheng Wang, et al.

  • Open Access

    Casticin induces apoptosis and G0/G1 cell cycle arrest in gallbladder cancer cells

    by Xiao-Ling Song, Yun-Jiao Zhang, Xue-Feng Wang, Wen-Jie Zhang, Zheng Wang, Fei Zhang, Yi-Jian Zhang, Jian-Hua Lu, Jia-Wei Mei, Yun-Ping Hu, et al.

    Casticin, the flavonoid extracted from Vitex rotundifolia L, exerts various biological effects, including anti-inflammatory and anti-cancer activity. The aim of this study is to investigate the effects and mechanisms of casticin in human gallbladder cancer cells. Human NOZ and SGC996 cells were used to perform the experiments. CCK-8 assay and colony formation assay were performed to evaluate cell viability. Cell cycle analyses and annexin V/PI staining assay for apoptosis were measured using flow cytometry. Western blot analysis was used to evaluate the changes in protein expression, and the effect of casticin treatment in vivo was experimented with xenografted tumors. In this study, we found that casticin significantly inhibited gallbladder cancer cell proliferation in a dose- and time-dependent manner. Casticin also induced G0/G1 arrest and mitochondrial-related apoptosis by upregulating Bax, cleaved caspase-3, cleaved caspase-9 and cleaved poly ADP-ribose polymerase expression, and by downregulating Bcl-2 expression. Moreover, casticin induced cycle arrest and apoptosis by upregulating p27 and downregulating cyclinD1/cyclin-dependent kinase4 and phosphorylated protein kinase B. In vivo, casticin inhibited tumor growth. Casticin induces G0/G1 arrest and apoptosis in gallbladder cancer, suggesting that casticin might represent a novel and effective agent against gallbladder cancer.


  • Open Access

    Dioscin Induces Gallbladder Cancer Apoptosis by Inhibiting ROS-Mediated PI3K/AKT Signalling

    by Xiaoling Song, Zheng Wang, Haibin Liang, Wenjie Zhang, Yuanyuan Ye, HuaiFeng Li, Yunping Hu, Yijian Zhang, Hao Weng, Jianhua Lu, et al.

    Gallbladder cancer (GBC), highly aggressive form of cancer with an extremely poor prognosis, is the most common malignancy of the biliary tract. In this study, we investigated the effects of dioscin (DSN) on human GBC and the potential mechanisms underlying these effects. The results showed that DSN significantly inhibited GBC cell proliferation and migration. Moreover, DSN induced GBC cell apoptosis via mitochondrial dependent apoptotic signalling. Reactive oxygen species (ROS) and glutathione (GSH) levels were measured, and ROS scavengers completely inhibited DSN-induced apoptosis and migration, indicating that ROS play an essential role in GBC progression. Western blot analysis showed that AKT activity was significantly downregulated after DSN treatment, and that inhibition/ectopic expression of AKT enhanced/abolished DSN-induced apoptosis but not migration. Furthermore, we confirmed the relationship between ROS and the PI3K/AKT pathway and found that DSN induced apoptosis by regulating ROS-mediated PI3K/AKT signaling. Taken together, these findings indicate that DSN induces GBC apoptosis through inhibiting ROS-mediated PI3K/AKT signalling.


  • Retracted

    RETRACTED ARTICLE: Chloride intracellular channel 1 (CLIC1) is activated and functions as an oncogene in pancreatic cancer

    by Jianhua Lu, Qian Dong, Bingtai Zhang, Xuefeng Wang, Bin Ye, Fei Zhang, Xiaoling Song, Guofeng Gao, Jiasheng Mu, Zheng Wang, et al.

    Chloride intracellular channel 1 (CLIC1), a newly discovered member of the chloride channel protein family, has been implicated in multiple human cancers. However, little is known with regard to its expression and biological functions in pancreatic cancer. In this study, we focused on the clinical significance and biological functions of CLIC1 in pancreatic cancer and found that this protein was overexpressed in pancreatic cancer tissues. Patients with CLIC1-positive tumours had worse overall survival than those with CLIC1-negative tumours. Furthermore, the treatment of pancreatic cancer cell lines with CLIC1-targeting siRNA oligonucleotides significantly reduced cell proliferation and diminished anchorage-independent growth on both soft agar and cell migration. These data indicate that CLIC1 acts as a putative oncogene in pancreatic cancer and may represent a novel diagnostic and therapeutic target for pancreatic cancer.